Applications to the FDA for orphan drug status for Marshall Protocol medications

Autoimmunity Research FoundationNon-profit foundation dedicated to exploring a pathogenesis and therapy for chronic disease. has submitted multiple applications to the Office of Orphan Products Development, a division of the FDA. The goal of submitting these applications would be to make it easier for doctors to prescribe and harder for insurance companies to deny coverage of MP medications.

Minocycline

Clindamycin

<html> <!–

Olmesartan

–!</html>